Macugen is available for your patients with neovascular (wet) age-related macular degeneration (AMD).

Macugen (pegaptanib sodium injection) is a sterile, aqueous solution containing pegaptanib sodium for intravitreous injection. Macugen solution is supplied in a single-dose, pre-filled syringe.

Pegaptanib is a selective vascular endothelial growth factor (VEGF) antagonist. VEGF is a secreted protein that selectively binds and activates its receptors located primarily on the surface of vascular endothelial cells. VEGF induces angiogenesis, and increases vascular permeability and inflammation, all of which are thought to contribute to the progression of the neovascular (wet) form of age-related macular degeneration (AMD), a leading cause of blindness.

Macugen can be used as maintenance therapy with recommended dosing every 6 weeks.

To order for your patients call 1.888.767.7123 or visit www.besse.com

Ordering Macugen made easy with Besse Medical

  1. CALL Besse Medical 1.888.767.7123 to order MACUGEN
  2. CONFIRM that you have an existing account
  3. PLACE an order and it will be shipped the next day

First-time prescribers of Macugen can register with Besse Medical by signing up for an account at www.besse.com/business-application.


Personalized patient assistance with the Focus on Access (FOA) program

For MacugenInformation on Reimbursement and Patient Assistance Services, call the FOCUS ON ACCESS Hotline, (866)-272-8838 (Monday-Friday, 9 AM to 5 PM EST).

 Download the Focus on Access Enrollment Form

  • FOA helps eligible patients secure access to Macugen
  • Patients may also receive reimbursement counseling
  • Patients and physicians complete the Download the enrollment form and FOA will provide a timely response

Indication

Macugen (pegaptanib sodium injection) is indicated for the treatment of neovascular (wet) age-related macular degeneration.

Important Safety Information

  • Macugen (pegaptanib sodium injection) is contraindicated in patients with ocular or periocular infections, and in patients with known hypersensitivity to pegaptanib sodium or any other excipient in this product.
  • Intravitreous injections, including those with Macugen, have been associated with endophthalmitis. Proper aseptic injection technique should always be utilized when administering Macugen. In addition, patients should be monitored during the week following the injection to permit early treatment, should an infection occur.
  • Increases in intraocular pressure have been seen within 30 minutes of injection with Macugen. Therefore, intraocular pressure as well as the perfusion of the optic nerve head should be monitored and managed appropriately.
  • Rare cases of anaphylaxis/anaphylactoid reactions, including angioedema, have been reported in post-marketing experience following the Macugen intravitreal administration procedure.
  • Serious adverse events related to the injection procedure occurring in <1% of intravitreous injections included endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.
  • Most common adverse reactions (reported in 10-40% of patients treated with Macugen for up to two years) are anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure (IOP), ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters, and vitreous opacities.

Click here for Prescribing Information

Macugen (pegaptanib sodium injection) : Additional information



MAC.0022.USA.17